NRIX Long Call Strategy
NRIX (Nurix Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX (Nurix Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.98B, a beta of 1.87 versus the broader market, a 52-week range of 8.195-23.715, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 314 full-time employees. These structural characteristics shape how NRIX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.87 indicates NRIX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on NRIX?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current NRIX snapshot
As of June 30, 2026, spot at $24.15, ATM IV 112.00%, IV rank 15.70%, expected move 32.11%. The long call on NRIX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on NRIX specifically: NRIX IV at 112.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a NRIX long call, with a market-implied 1-standard-deviation move of approximately 32.11% (roughly $7.75 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NRIX expiries trade a higher absolute premium for lower per-day decay. Position sizing on NRIX should anchor to the underlying notional of $24.15 per share and to the trader's directional view on NRIX stock.
NRIX long call setup
The NRIX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NRIX near $24.15, the first option leg uses a $24.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NRIX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NRIX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $24.00 | $2.65 |
NRIX long call risk and reward
- Net Premium / Debit
- -$265.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$265.00
- Breakeven(s)
- $26.65
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
NRIX long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on NRIX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$265.00 |
| $5.35 | -77.9% | -$265.00 |
| $10.69 | -55.7% | -$265.00 |
| $16.03 | -33.6% | -$265.00 |
| $21.36 | -11.5% | -$265.00 |
| $26.70 | +10.6% | +$5.30 |
| $32.04 | +32.7% | +$539.16 |
| $37.38 | +54.8% | +$1,073.02 |
| $42.72 | +76.9% | +$1,606.87 |
| $48.06 | +99.0% | +$2,140.73 |
When traders use long call on NRIX
Long calls on NRIX express a bullish thesis with defined risk; traders use them ahead of NRIX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
NRIX thesis for this long call
The market-implied 1-standard-deviation range for NRIX extends from approximately $16.40 on the downside to $31.90 on the upside. A NRIX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current NRIX IV rank near 15.70% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NRIX at 112.00%. As a Healthcare name, NRIX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NRIX-specific events.
NRIX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NRIX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NRIX alongside the broader basket even when NRIX-specific fundamentals are unchanged. Long-premium structures like a long call on NRIX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NRIX chain quotes before placing a trade.
Frequently asked questions
- What is a long call on NRIX?
- A long call on NRIX is the long call strategy applied to NRIX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With NRIX stock trading near $24.15, the strikes shown on this page are snapped to the nearest listed NRIX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NRIX long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the NRIX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 112.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$265.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NRIX long call?
- The breakeven for the NRIX long call priced on this page is roughly $26.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NRIX market-implied 1-standard-deviation expected move is approximately 32.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on NRIX?
- Long calls on NRIX express a bullish thesis with defined risk; traders use them ahead of NRIX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current NRIX implied volatility affect this long call?
- NRIX ATM IV is at 112.00% with IV rank near 15.70%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.